Samuel Wilkinson, M.D.


Samuel Wilkinson, M.D.
Assistant Professor & Assistant Director
Yale Depression Research Program
Yale School of Medicine

Presentation:  Ketamine for the use of Psychiatric Disorders

Dr. Wilkinson graduated from medical school at John Hopkins University and completed his psychiatric residency training at Yale. He is now Assistant Professor at Yale and is the Assistant Director of the Yale Depression Research Program. His research interests focus on developing ways to improve the quality of care in the community for psychiatric patients, treatment development (clinical trials), and has a special interest in improving access to and dissemination of preventive measures and evidence-based therapies for treatment-resistant depression. These include electroconvulsive therapy (ECT). He is also interested in novel therapeutics, including research examining the rapid-acting antidepressant effects of ketamine and related compounds. He also has an interest in the potential therapeutic and adverse effects of cannabinoids as well as US policy relating to the medical and recreational use of cannabinoids.

Disclosure: Dr. Wilkinson has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

  • Consultant: Janssen, Biohaven, and Oui Therapeutics
  • Other: Received funding to conduct clinical trials from Janssen and Sage Therapeutics, administered through Yale University

Review of Conflicts Policy:  The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming.  For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director.  If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.